Antibody Response to Vaccination with Myeloid and Lymphoid Neoplasms - report from ASH2021

Professor Susanne Saussele speaks about antibody response to vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms. In general, patients with hematological diseases are predisposed to develop infections. Severe COVID-19 infection associated with high mortality is more likely in these patient cohorts compared to the general population. Due to immune defects related to the primary disease and/or to immunosuppressive treatment regimes, vaccination efficacy may be reduced in patients with hematological diseases. So far, data on this area are limited. Video: https://congressreport.eu/scientific-contents/interview:antibody-response-vaccination-myeloid-and-lymphoid-neoplasms